Table 3.

Characteristics of fecal microbiota transplantation for pouchitis.

Study	N	Age (y)	Disease Activity	Delivery	Frequency	Donor	Dosage	Primary endpoint	Follow up	Remission	Response
Landy et al., 2015	8	24–63	Chronic antibiotic refractory Pouchetis,PDAI ≥ 7	Nasogastric	1	NR	18 g stool/30 ml saline solution)	PDAI ≤ 4	4 weeks	0%	25%
Nishida et al., 2019	3	24–52	PDAI ≥ 7	Colonoscopy	1	Related	NR	Reduction in total PDAI ≥ 3 at 8 weeks	8 weeks	0%	33%
Stallmach et al., 2016	5	26–40	Chronic antibiotic refractory pouchitis, PDAI 9–14	Jejunum via upper gastrointestinal tract endoscopy	1–7 (3–4 weeks intervals)	Two unrelated	75 g stool in 200 ml saline	NR	3 months	80% at 4 weeks, 60% at 3 months	100%
Herfarth et al., 2019	6	22–60	Chronic antibiotic refractory pouchi- tis (mPDAI≥5 and a history of ≥4 antibiotic therapies for pouchitis in the last 12 months)	Endoscopic (eFMT) and oral encapsulated (oFMT)	eFMT: 2; oFMT: daily for 14 days	Unrelated	eFMT: 12 g stool in 30 ml; oFMT: 4.2 g stool	The safety of the combined eFMT and oFMT	16 weeks	17%	17%
Selvig et al., 2020	19	18-74	Chronic pouchitis (pouch symptoms > 4 weeks and endoscopic evaluation con- frming infamma- tion of the pouch	Pouchoscopy	1–2	12 months	250 ml donor fecal suspen- sion (25 g stool)	Clinical improvement at week 4.	12 months	0	9% (among patients receiving double FMT)

PDAI, Pouchitis Disease Activity Index; FMT, fecal microbiota transplantation; eFMT, endoscopic FMT; oFMT, oral encapsulated FMT.